Longitudinal brain perfusion changes correlated with UPDRS Total in a Phase I mesenchymal stem cell trial for Parkinson’s disease
Objective: Explore changes in correlations between brain perfusion and UPDRS-Total (UPDRS-T) after a single infusion of allogeneic bone marrow-derived mesenchymal stem cells (MSC). Background: Our…Clinical and biomarker characteristics of Huntington’s Disease patients recently proposed for huntingtin-lowering clinical trial inclusion
Objective: We investigated plasma NfL levels, as well as clinical measures, in Huntingtin (Htt)-mutation carriers 48 years of age and under, with a CAP score…Neuroprotective trial design methodology for Parkinson’s: a scoping review
Objective: To further understanding of the diversity and impact of trial design choices in trials of disease modifying therapy (DMT) in Parkinson’s disease (PD). Background:…Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for the treatment of Parkinson’s Disease
Objective: To compare and contrast nilotinib and vodobatinib regarding efficacy, brain penetration, and safety. Background: Preclinical evidence suggests that c-Abl is critical for pathogenesis of…An AAV9 encoding human ABCD1 (SBT101) shows functional improvement following spinal cord delivery in a rodent model of adrenomyeloneuropathy
Objective: SBT101 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy candidate delivering a functional copy of the human ABCD1 gene that is in development…Nutritional Status of Patients with Parkinson’s Disease: Report from Indonesian Tertiary Referral Hospital
Objective: This study aimed to describe and determine the prevalence of nutritional status in outpatient Parkinson’s Disease (PD) patients. Background: Parkinson’s disease is the most…Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study
Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION
Objective: To evaluate whether long-term statin use may affect motor progression in a large cohort of de novo patients with Parkinson's Disease. Background: Statins are…Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials
Objective: To assess risk attitudes of patients suffering from multiple system atrophy (MSA) and Parkinson’s disease (PD) on future disease-modifying therapies as well as related…Rapamycin attenuates nigral and hippocampal alpha-synuclein accumulation in AAV-mediated alpha-synuclein overexpression model of Parkinson’s disease
Objective: To examine the possible neurorestorative effects of chronic rapamycin treatment in AAV-mediated alpha-synuclein (a-syn) overexpression model of Parkinson’s disease (PD), designed to induce hippocampal…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 22
- Next Page »